Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial ...

GLP-1 receptor agonists are reshaping obesity care. OHE highlights access challenges, prescribing policy, and how patient and ...

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...

Medicare recipients suffering from obesity must pay out of pocket for weight loss drugs like Wecovy and Zepbound.

How can policy makers and health care leaders ensure affordable, equitable access to GLP-1 medications while managing their ...

Eli Lilly and Company's stock dropped 11% after CVS's Zepbound exclusion, but analysts see a mispricing opportunity. Click ...

Eli Lilly on Thursday posted better-than-expected quarterly results, but CVS Health's decision to drop the company's obesity ...

Eli Lilly on Thursday posted better-than-expected quarterly results, but CVS Health's decision to drop the company's obesity ...

While medication and other treatments are out of reach for many, I’ve recently learned TennCare is exploring adding coverage ...

IANS New Delhi: A common diabetes drug can help reduce pain in people with knee osteoarthritis (OA) and obesity, as well as delay the need for knee replacements, revealed a study on Friday.

In Wyoming, we pride ourselves on facing challenges head-on. Whether it's weathering tough winters or tackling rural health care gaps, we don't back down. That's why it's frustrating to hear that ...

This study contributes to the growing body of evidence supporting the efficacy of tirzepatide in obesity management and underscores the importance of continued research into its metabolic effects ...